Table 5.

Salient Drug Interactions of Drugs for HCV with HAART.

Daclatasvir	• Reduce daclatasvir dose to 30 mg/day with strong CYP3A4 inhibitors (ritonavir-boosted atazanavir, bocepravir, telprevir, and cobicistat). • Increase daclatasvir dose to 90 mg when it is administered with inducers of CYP3A4 (efavirenz and etravirine)
Ledipasvir	• Avoid with tenofovir in creatinine clearance <60 mL/min or along with ritonavir-boosted protease inhibitors. • Avoid with cobicistat/elvitegravir combination therapy
Sofosbuvir	• Not recommended for use with tipranavir
Ribavirin	• Avoid with zidovudine, didanosine or stavudine